moxonidine

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.12 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	88 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.80 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.93 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.20 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.80 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Bocci G, Oprea TI, Benet LZ

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-0.320		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.871		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	4.305	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	2.649	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	89.330	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	85.680	%	High	1
herg	hERG pIC50	4.271	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	1	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	3.258	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	79.510	%	High	1
kinase-safety-class	ACVR2B,AURKA,AXL,BRAF,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,MAP3K21,MAPK7,MARK4,NTRK2,PDK1,PDK2,PIK3CB,PIK3CD,PRKDC,SIK2,STK33,TEK,TTK	26
kinase-selectivity-class	GRK2	1
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	1.455		High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	1.614		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	3.006		High	1
mppb	Mouse plasma protein binding (% unbound)	92.470		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	2.051		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	85.790	%	High	1
rat-kpuu-brain	Rat brain Kpuu	0.158	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	2.399	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	95.300	%	High	1
rppb	Rat plasma protein binding (% unbound)	87.060	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	939.723	uM	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	225.01	25.90	113	5085	105308	90517941
Serositis	155.70	25.90	31	5167	1286	90621963
Body mass index abnormal	134.60	25.90	25	5173	714	90622535
Central nervous system lupus	119.33	25.90	25	5173	1338	90621911
Hyperkalaemia	107.99	25.90	59	5139	64905	90558344
General physical health deterioration	98.38	25.90	111	5087	355004	90268245
Hypertensive crisis	89.88	25.90	35	5163	17749	90605500
Haematuria	87.95	25.90	42	5156	34895	90588354
Lupus nephritis	87.89	25.90	25	5173	4807	90618442
Product prescribing error	84.39	25.90	39	5159	30106	90593143
Lactic acidosis	78.80	25.90	44	5154	50419	90572830
Acute kidney injury	71.86	25.90	90	5108	320297	90302952
Cardiac failure	70.86	25.90	55	5143	109441	90513808
Gout	63.93	25.90	27	5171	16832	90606417
Electrocardiogram abnormal	51.07	25.90	20	5178	10278	90612971
Stevens-Johnson syndrome	46.89	25.90	26	5172	29350	90593899
Bradycardia	41.37	25.90	36	5162	83811	90539438
Electrolyte imbalance	37.85	25.90	21	5177	23724	90599525
Hyperammonaemia	37.20	25.90	14	5184	6461	90616788
Abdominal pain	36.41	25.90	74	5124	395647	90227602
Language disorder	36.26	25.90	11	5187	2641	90620608
Traumatic haemorrhage	35.67	25.90	8	5190	589	90622660
Therapeutic drug monitoring analysis not performed	34.03	25.90	9	5189	1320	90621929
Mental disability	31.54	25.90	6	5192	195	90623054
Peripheral arterial occlusive disease	30.26	25.90	11	5187	4610	90618639
Blood creatinine increased	30.18	25.90	33	5165	101353	90521896
Hyperglycaemia	29.49	25.90	24	5174	50946	90572303
Renal failure	28.00	25.90	36	5162	130971	90492278
Left ventricular hypertrophy	27.21	25.90	11	5187	6133	90617116
Eye movement disorder	27.12	25.90	11	5187	6187	90617062
Orthostatic hypotension	26.99	25.90	21	5177	41806	90581443
Drug interaction	26.95	25.90	53	5145	276400	90346849
Genotype drug resistance test positive	26.74	25.90	6	5192	443	90622806

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	66.20	22.17	132	4525	367205	42249473
Basal cell carcinoma	62.86	22.17	36	4621	22697	42593981
Labelled drug-drug interaction medication error	57.86	22.17	30	4627	15552	42601126
Product prescribing error	55.71	22.17	35	4622	26077	42590601
Benign gastrointestinal neoplasm	55.14	22.17	10	4647	126	42616552
Hemiparaesthesia	51.34	22.17	10	4647	189	42616489
Hyperkaliuria	51.09	22.17	9	4648	95	42616583
Superficial spreading melanoma stage I	43.84	22.17	7	4650	38	42616640
Hyperkalaemia	42.44	22.17	48	4609	80410	42536268
Papillary renal cell carcinoma	40.04	22.17	9	4648	347	42616331
Product monitoring error	37.03	22.17	15	4642	4408	42612270
Peripheral artery stenosis	36.25	22.17	10	4647	897	42615781
Linear IgA disease	35.71	22.17	12	4645	2091	42614587
Schizophrenia	35.43	22.17	19	4638	10531	42606147
Polypectomy	34.71	22.17	9	4648	637	42616041
Hypotension	34.14	22.17	82	4575	257549	42359129
Drug interaction	31.18	22.17	81	4576	266918	42349760
Hypertensive crisis	30.45	22.17	17	4640	10189	42606489
Sprue-like enteropathy	29.91	22.17	8	4649	639	42616039
Histology abnormal	29.51	22.17	7	4650	343	42616335
Chylothorax	29.39	22.17	9	4648	1165	42615513
Inappropriate affect	28.67	22.17	8	4649	748	42615930
Suspected product contamination	27.48	22.17	6	4651	202	42616476
Renal impairment	25.16	22.17	44	4613	110184	42506494
Bradycardia	24.75	22.17	38	4619	85446	42531232
Periodontitis	23.81	22.17	9	4648	2202	42614476
Death	23.68	22.17	11	4646	471174	42145504
Manufacturing materials contamination	23.59	22.17	4	4653	33	42616645
Cardiac failure	23.54	22.17	42	4615	106814	42509864
Dizziness	23.51	22.17	70	4587	249184	42367494
Paradoxical drug reaction	23.15	22.17	11	4646	4727	42611951
Product contamination	22.27	22.17	7	4650	988	42615690

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	190.39	19.24	144	9165	188301	110391689
Acute kidney injury	150.43	19.24	223	9086	635207	109944783
Hyperkalaemia	141.99	19.24	106	9203	135690	110444300
Product prescribing error	140.79	19.24	74	9235	51257	110528733
Serositis	138.39	19.24	31	9278	1538	110578452
Body mass index abnormal	119.32	19.24	25	9284	903	110579087
Central nervous system lupus	109.93	19.24	25	9284	1328	110578662
Hypertensive crisis	105.49	19.24	48	9261	24324	110555666
General physical health deterioration	90.07	19.24	142	9167	425153	110154837
Lupus nephritis	79.37	19.24	25	9284	4620	110575370
Labelled drug-drug interaction medication error	76.79	19.24	41	9268	29261	110550729
Cardiac failure	67.45	19.24	81	9228	187545	110392445
Bradycardia	64.02	19.24	72	9237	155445	110424545
Basal cell carcinoma	62.68	19.24	42	9267	45228	110534762
Drug interaction	61.37	19.24	132	9177	500051	110079939
Benign gastrointestinal neoplasm	57.45	19.24	10	9299	130	110579860
Lactic acidosis	56.40	19.24	53	9256	92758	110487232
Hyperkaliuria	54.09	19.24	10	9299	186	110579804
Hypotension	52.88	19.24	128	9181	523721	110056269
Haematuria	49.66	19.24	47	9262	82958	110497032
Hemiparaesthesia	46.78	19.24	10	9299	398	110579592
Product contamination	44.13	19.24	13	9296	1918	110578072
Electrolyte imbalance	43.37	19.24	31	9278	36997	110542993
Superficial spreading melanoma stage I	43.20	19.24	7	9302	57	110579933
Product monitoring error	43.14	19.24	19	9290	8908	110571082
Peripheral artery stenosis	39.39	19.24	11	9298	1343	110578647
Gout	36.93	19.24	28	9281	36538	110543452
Papillary renal cell carcinoma	36.44	19.24	8	9301	361	110579629
Dizziness	35.52	19.24	134	9175	698059	109881931
Blood creatinine increased	33.10	19.24	57	9252	182832	110397158
Urosepsis	32.11	19.24	24	9285	30651	110549339
Hypoglycaemia	30.54	19.24	43	9266	116061	110463929
Histology abnormal	30.34	19.24	7	9302	396	110579594
Linear IgA disease	30.14	19.24	12	9297	4377	110575613
Hyperglycaemia	29.34	19.24	36	9273	85054	110494936
Polypectomy	29.25	19.24	9	9300	1540	110578450
Arrhythmia	28.24	19.24	32	9277	69543	110510447
Language disorder	28.14	19.24	11	9298	3827	110576163
Renal failure	27.93	19.24	60	9249	226514	110353476
Suspected product contamination	27.33	19.24	6	9303	271	110579719
Therapeutic drug monitoring analysis not performed	27.29	19.24	9	9300	1922	110578068
Schizophrenia	27.24	19.24	19	9290	21807	110558183
Drug hypersensitivity	25.26	19.24	4	9305	454086	110125904
Osteochondrosis	24.94	19.24	9	9300	2512	110577478
Manufacturing materials contamination	24.64	19.24	4	9305	33	110579957
Sprue-like enteropathy	24.35	19.24	8	9301	1688	110578302
Inappropriate affect	24.34	19.24	8	9301	1691	110578299
Lichen planopilaris	24.30	19.24	5	9304	165	110579825
Traumatic haemorrhage	23.70	19.24	8	9301	1836	110578154
Blood aldosterone increased	22.86	19.24	5	9304	222	110579768
Glomerular filtration rate decreased	22.47	19.24	19	9290	28937	110551053
Infected lymphocele	22.40	19.24	5	9304	244	110579746
Hyperammonaemia	22.08	19.24	14	9295	13718	110566272
Syncope	21.99	19.24	51	9258	202485	110377505
Tumour lysis syndrome	21.45	19.24	19	9290	30782	110549208
Disorientation	21.35	19.24	28	9281	70643	110509347
Circulatory collapse	21.34	19.24	22	9287	42971	110537019
Dehydration	20.72	19.24	61	9248	279450	110300540
Postrenal failure	20.47	19.24	6	9303	870	110579120
Joint swelling	20.37	19.24	6	9303	442839	110137151
Parvovirus B19 infection	20.22	19.24	8	9301	2873	110577117
Skin squamous cell carcinoma recurrent	20.14	19.24	4	9305	110	110579880
Erysipelas	20.13	19.24	13	9296	13145	110566845
Pain	19.98	19.24	31	9278	954924	109625066
Urogenital infection bacterial	19.87	19.24	4	9305	118	110579872
Orthostatic hypotension	19.63	19.24	26	9283	66223	110513767
Renin decreased	19.53	19.24	4	9305	129	110579861
Tachypnoea	19.27	19.24	20	9289	39375	110540615

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

moxonidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Source	Code	Description
ATC	C02AC05	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, CENTRALLY ACTING Imidazoline receptor agonists
ATC	C02LC05	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Imidazoline receptor agonists in combination with diuretics
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:50514	vasoconstrictor agent

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Nischarin	Membrane receptor	Q9Y2I1	NISCH_HUMAN	AGONIST	Ki	8.38	CHEMBL	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.40	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN	AGONIST	IC50	7.50	IUPHAR
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	5.70	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.82	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.15	CHEMBL
Nischarin	Membrane receptor		NISCH_RAT		Ki	7.11	CHEMBL
Alpha-2B adrenergic receptor	GPCR		ADA2B_RAT		Ki	6	CHEMBL

ID	Source
D05087	KEGG_DRUG
C0066837	UMLSCUI
CHEBI:7009	CHEBI
CHEMBL19236	ChEMBL_ID
DB09242	DRUGBANK_ID
4810	PUBCHEM_CID
C043482	MESH_SUPPLEMENTAL_RECORD_UI
12574	IUPHAR_LIGAND_ID
5207	INN_ID
CC6X0L40GW	UNII
30257	RXNORM
006139	NDDF
318706009	SNOMEDCT_US
395805008	SNOMEDCT_US

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.96	Basic
pKa2	2.26	Basic